Verastem | VSTM - Pre Tax Profit


Verastem reported $-33.86M in Pre-Tax Profit for its fiscal quarter ending in March of 2024.





Pre Tax Profit Change Date
AbbVie USD 4.38B 1.92B Sep/2025
Alaunos Therapeutics USD -7.84M 633K Dec/2023
AstraZeneca USD 3.24B 117M Sep/2025
Curis USD -13.99M 7.38M Jun/2025
Cytokinetics USD -183.03M 123.15M Dec/2025
Gilead Sciences USD 3.64B 1.21B Sep/2025
Incyte USD 389.94M 92.37M Dec/2025
Laboratory Of America USD 337M 32.3M Sep/2025
Novartis USD 4.64B 445M Dec/2025
Pfizer USD 3.33B 290M Sep/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
TG Therapeutics USD 45.09M 19.18M Dec/2025
Verastem USD -33.86M 6.49M Mar/2024